What Is the Treatment of Advanced or Metastatic Dedifferentiated Liposarcoma?
Dedifferentiated liposarcoma (DDLPS) at an advanced or metastatic stage is a distinct clinical entity that requires a specific systemic approach. The front-line strategy is well defined and depends on the disease's pace and extent.
Clinical Scenario
This protocol addresses patients with advanced or metastatic dedifferentiated liposarcoma. Disease characteristics — including the extent of metastasis, rate of progression, and symptom burden — determine which variant of the front-line regimen applies.
Front-Line Treatment Approach
The established standard centres on anthracycline-based chemotherapy as the foundation of first-line systemic treatment. Specific clinical factors determine whether a single-agent or a combination approach is used — the complete protocol specifies these criteria and the full regimen.
References
DOI: 10.1016/j.ctrv.2024.102846
- Anthracycline-based therapy, either as a single agent (doxorubicin or epirubicin) or as part of a combination (doxorubicin or epirubicin in combination with ifosfamide), is considered the front-line standard for metastatic DDLPS.
- While significant progress has been made in the systemic treatment of liposarcoma, standard first-line chemotherapy for DDLPS remains an anthracycline-based regimen, most commonly doxorubicin at a dose of 75 mg/m2/cycle.
- However, response rates are higher with combination treatment, thus the addition of ifosfamide is considered in patients with oligometastatic disease who could go on to potentially curative treatments or for those patients with rapidly progressive and/or symptomatic disease.
View source ↗